BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36251015)

  • 21. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
    Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
    Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SOX9 modulates cancer biomarker and cilia genes in pancreatic cancer.
    Edelman HE; McClymont SA; Tucker TR; Pineda S; Beer RL; McCallion AS; Parsons MJ
    Hum Mol Genet; 2021 Apr; 30(6):485-499. PubMed ID: 33693707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Schmitt A; Feldmann G; Zander T; Reinhardt HC
    Oncol Res Treat; 2018; 41(10):619-625. PubMed ID: 30286473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility of ATM-deficient pancreatic cancer cells to radiation.
    Ayars M; Eshleman J; Goggins M
    Cell Cycle; 2017 May; 16(10):991-998. PubMed ID: 28453388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. REV7 is involved in outcomes of platinum-based chemotherapy in pancreatic cancer by controlling the DNA damage response.
    Tamaki A; Kato T; Sakurai Y; Sato K; Adachi K; Tadehara M; Kogami T; Matsushita M; Hoshino A; Sanoyama I; Numata Y; Umezawa A; Ichinoe M; Ichihara M; Kusano C; Murakumo Y
    Cancer Sci; 2024 Feb; 115(2):660-671. PubMed ID: 38130032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
    Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
    Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma.
    Yang T; Shen P; Chen Q; Wu P; Yuan H; Ge W; Meng L; Huang X; Fu Y; Zhang Y; Hu W; Miao Y; Lu Z; Jiang K
    J Exp Clin Cancer Res; 2021 Aug; 40(1):261. PubMed ID: 34416910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
    Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
    J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
    Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
    EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EUS-based Pancreatic Cancer Surveillance in
    Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATR inhibition sensitizes HPV
    Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
    Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
    Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
    Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
    Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
    Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
    Capula M; Perán M; Xu G; Donati V; Yee D; Gregori A; Assaraf YG; Giovannetti E; Deng D
    Drug Resist Updat; 2022 Sep; 64():100864. PubMed ID: 36115181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AKR7A3 modulates the metastasis of pancreatic ductal adenocarcinoma through regulating PHGDH-suppressed autophagy.
    Hua L; Song Y; Min J; Wang R; Li H; Zhu L; Guo Y; Gan D; Li S; Ma P; Yang C; Yang J; Shi J; Li J; Su H
    Cancer Sci; 2023 Aug; 114(8):3101-3113. PubMed ID: 36951402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer.
    Drosos Y; Escobar D; Chiang MY; Roys K; Valentine V; Valentine MB; Rehg JE; Sahai V; Begley LA; Ye J; Paul L; McKinnon PJ; Sosa-Pineda B
    Sci Rep; 2017 Sep; 7(1):11144. PubMed ID: 28894253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.